Caltrate 600 mg/400 IU, Film-coated Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

caltrate 600 mg/400 iu, film-coated tablets

pfizer healthcare ireland - calcium carbonate; cholecalciferol concentrate - film-coated tablet - 600 mg/400 international unit(s) - calcium, combinations with vitamin d and/or other drugs

Caltrate 500 mg / 1000 IU, chewable tablets Ireland - English - HPRA (Health Products Regulatory Authority)

caltrate 500 mg / 1000 iu, chewable tablets

pfizer healthcare ireland - calcium carbonate; cholecalciferol concentrate - chewable tablet - 500 mg/1000 international unit(s) - calcium, combinations with vitamin d and/or other drugs

CALTRATE calcium 600mg (as carbonate) tablet      bottle Australia - English - Department of Health (Therapeutic Goods Administration)

caltrate calcium 600mg (as carbonate) tablet bottle

haleon australia pty ltd - calcium carbonate, quantity: 1499 mg (equivalent: calcium, qty 600 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; light liquid paraffin; crospovidone; povidone; sodium lauryl sulfate; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - assists in preventing and treating osteoporosis. calcium supplement.

Caltrate 500 mg / 1000 IU, chewable tablets Ireland - English - HPRA (Health Products Regulatory Authority)

caltrate 500 mg / 1000 iu, chewable tablets

glaxosmithkline consumer healthcare (ireland) limited - cholecalciferol concentrate ; calcium carbonate - chewable tablet - 500 mg/1000 international unit(s) - calcium, combinations with vitamin d and/or other drugs

Caltrate 600 mg/400 IU, Film-coated Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

caltrate 600 mg/400 iu, film-coated tablets

haleon ireland limited - calcium carbonate; cholecalciferol concentrate - film-coated tablet - 600 mg/400 international unit(s) - calcium, combinations with vitamin d and/or other drugs

ALENDRONATE PLUS D3 CAL alendronic acid (as sodium) 70 mg and colecalciferol 140 microgram tablet and calcium 500 mg tablet comp Australia - English - Department of Health (Therapeutic Goods Administration)

alendronate plus d3 cal alendronic acid (as sodium) 70 mg and colecalciferol 140 microgram tablet and calcium 500 mg tablet comp

dr reddys laboratories australia pty ltd - calcium carbonate, quantity: 1.25 g (equivalent: calcium, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; croscarmellose sodium; povidone; magnesium stearate; hypromellose; macrogol 8000; chlorophyllin-copper complex; titanium dioxide; carnauba wax - for the treatment of: ? osteoporosis in select patients where vitamin d and calcium supplementation is recommended,prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

PREMARIN- conjugated estrogens tablet, film coated United States - English - NLM (National Library of Medicine)

premarin- conjugated estrogens tablet, film coated

aphena pharma solutions - tennessee, inc. - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - estrogens, conjugated 0.625 mg - premarin therapy is indicated in the: - treatment of moderate to severe vasomotor symptoms due to menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of postmenopausal osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered. the mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin d in